US EditionPharmaceutical Outsourcing Evolution: The Rise of Clinical Peripheral Services
Summary by frost.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Pharmaceutical Outsourcing Evolution: The Rise of Clinical Peripheral Services
The Expanding Role of Clinical Contract Peripheral Services As the pharmaceutical and biopharma industries recalibrate after the COVID-19 pandemic, clinical trial outsourcing has surged, creating significant opportunities for contract research organizations (CROs). The global CRO industry, valued at $66.39 billion in 2024, is projected to grow at a CAGR of 10.7%, reaching $122.13 billion by 2030. With an outsourcing penetration rate of 45%-50%, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
